HOME >> BIOLOGY >> NEWS
Cellular dumping site is not garbage after all

Cells can reuse the chemical messengers that carry genetic information to the machinery that makes proteins. Sometimes cells shuttle the messengers to storage and later reactivate them to make proteins, according to new research.

Learning how cells regulate the newly discovered "mRNA cycle" may provide insights into how the cellular machinery runs amok in diseases like cancer.

Scientists had previously thought the messenger molecules, known as mRNAs, were manufactured, used, decommissioned and then sent on a one-way journey to the garbage dump.

These cellular garbage dumps, called P-bodies, turn out to be storage depots, not landfills. After use, mRNA molecules are temporarily deactivated for storage purposes. The cell can then either destroy the mRNA or recondition pre-used mRNA so it can be put back into service if needed.

P-bodies are also involved in determining whether specific mRNAs are used to make proteins, a process called translation.

"We were surprised to find that the P-bodies were involved in regulating translation," said research team leader Roy Parker, a Regents' Professor of molecular and cellular biology at The University of Arizona in Tucson and an Investigator with the Howard Hughes Medical Institute. In 2003, his lab was the first to name and describe a function for P-bodies.

Parker said of the new finding, "It suggests P-bodies have a much broader role in controlling the activities of the cell than we realized."

Parker and first author Jeff Coller report P-bodies' role in the control of translation in the Sept. 23 issue of the journal Cell. Coller, who did the research while at UA as a postdoctoral fellow with the Howard Hughes Medical Institute, is now an assistant professor in the Center for RNA Molecular Biology at Case Western Reserve University in Cleveland, Ohio.

The Parker lab's findings about P-bodies serving as storage depots was released online Sept. 1, 2005 and will be pu
'"/>

Contact: Mari N. Jensen
mnjensen@email.arizona.edu
520-626-9635
University of Arizona
22-Sep-2005


Page: 1 2 3

Related biology news :

1. Story ideas from Molecular & Cellular Proteomics
2. Cellular message movement captured on video
3. Cellular pathway yields potential new weapon in vaccine arsenal
4. Cellular cues identified for stroke recovery
5. Cellular killer also important to memory
6. Cellular traffic backups implicated in skeletal malformations
7. Cellular antennae on algae give clues to how human cells receive signals
8. Cellular scale drug delivery from the inside out
9. Cellular power plants also fend off viruses
10. World Wildlife Fund warns against iron dumping experiment near the Galapagos Islands
11. MIT warns of dumping seafood

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Cellular dumping site not garbage after all

(Date:2/24/2015)... DUBLIN , Feb. 24, 2015 Research ... announced the addition of the "Global 2D ... offering. The analysts forecast the ... a CAGR of 32.12% over the period 2014-2019 ... devices in non-traditional sectors is one of the ...
(Date:2/13/2015)... -- ACT Genomics Co., Ltd., a cancer molecular ... genomic information into precision diagnosis and personalized treatments, ... million in the its first private funding round. ... , ACT Genomics has developed comprehensive cancer ... implement next generation sequencing (NGS) and multiplex molecular ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2ACT Genomics Raises $8 Million in its First Private Funding Round 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34
(Date:2/27/2015)... 2015 A paper published today, " ... " in Science Translational Medicine, demonstrates ... reduce the risk associated with investing in the ... levels of funding for developing so-called "orphan" drugs. ... collaboration between scientists at the National Center for ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine ... and immunotherapy company, today announced that the U.S. ... for Fast Track designation and Phase I clinical ... conjunction with the mutual co-development agreement signed with ... Fast Track designation for the DPX-Survivac. , “We ...
(Date:2/27/2015)... , Feb. 27, 2015 Bionomics Limited ... the DisrupTOR-1 trial of BNC105 in patients with metastatic ... Orlando, Florida . The data will ... the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and IL-8 ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
Breaking Biology Technology:New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 2New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 3New Financing Technique May Hold Key to Unlocking Funding for Rare Diseases 4Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2
Cached News: